Table 2.
Merging knowledge from different studies.
| MIS-C | COVID |
|---|---|
| *MIS-C with severe myocarditis | |
| High levels of CSF2, CCL2, IL-6, CXCL10, FLT3L, 177 VEGF, TGF-A, IL-1RA, PD-L1, CX3CL1, TGF-B1 (51) | High IFNα (75) |
| Neutrophilia (75) | |
| Decreased NF-KB inhibitors* (51) | |
| Thrombocytopenia (75) | |
| Higher ratio neutrophils/lymphocytes (75) | |
| Increased S-100 proteins* (51) | |
| High MPO expression (80) | |
| Increased NF-KB expression* (51) | |
| Low plasmocytoid dendritic cells (75) | |
| Decreased MHC II expression* (51) | |
| High levels of IFNγ, IFNα2, IL-17A, TNF-α, IL-10, Granzyme B (51) | Lower levels of IFNγ, IFNα2, IL-17A, TNF-α, IL-10, Granzyme B compared to MIS-C (51) |
| High levels of IL-10 + TNF-α (20) | |
| High levels of Hypoxia induced response (HIF1-α)* (51) | |
| High levels of IFNα2 and IL-17A* (51) | |
| High SARS–CoV2 RT-PCR cycle threshold (20) | Low SARS–CoV2 RT-PCR cycle threshold (20) |
| Restricted antibody response, mainly anti-Spike antibodies, lower neutralizing activity (43) | Higher levels of specific antibodies with the most prominent neutralizing activity (43) |
| Lack of anti-N antibodies (43) | Presence of anti- N antibodies (43) |
| Overexpression of interferon induced genes (51) |
*
means MIS-C with severe myocarditis.